Eli Lilly and Co. has initiated clinical trials of LY2275796, an antisense drug that targets a protein involved in the growth and survival factors that contribute to tumor progression and the spread of cancers. LY2275796 was discovered in the Isis-Lilly drug discovery collaboration, and is the second antisense drug candidate from this strategic alliance to advance into Phase I development. Lilly will pay Isis Pharmaceuticals, Inc. $750,000 for the accomplishment of this milestone. Lilly is also ...